Nasus Pharma files Form 3 for Interim CFO Oren Elmaliah

NSRX•2026-09-23

Interim CFO files initial ownership report

Nasus Pharma interim CFO Oren Elmaliah filed an initial ownership report listing options for 52,140 ordinary shares exercisable at $1.23-$6.05.

Sources

Nasus Pharma files Form 3 for Interim CFO Oren Elmaliah

Sec

Nasus Pharma files Form 3 for Interim CFO Oren Elmaliah

Interim CFO files initial ownership report

Related News

Cox Capital Announces Tender Offers For Class I Shares Of Blackstone Private Credit Fund And HPS Corporate Lending Fund

Rupee slips as dollar gets Fed hike expectations tailwind

HPS Corporate Lending Fund - Aggregate NAV $12.26 Billion, Portfolio Fair Value $23.17 Billion, Debt $11.22 Billion As Of Aug 31, 2026

Sources

Nasus Pharma files Form 3 for Interim CFO Oren Elmaliah

Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus

Ac Immune Reports Positive Safety & Immunogenicity At Week-100 In Part 1 Of Vacsyn Phase 2 Trial Of Aci-7104